Abstract

The present invention relates to reverse micelle system comprising sterol, acylglycerol, alcohol, water, water-soluble active ingredient, phospholipid or sphingolipid, wherein the weight ratio phospholipid or sphingolipid/acylglycerol range from 0.05 to 0.55 and a further vegetable oil. The invention also relates to the preparation method of said reverse micelle system, their use and pharmaceutical composition comprising the same.

IPC Classes  ?

• A61K 9/107 - Emulsions
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
• A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids

Abstract

The disclosure relates to the treatment and/or prevention of radiation damage by administering a reverse micelle system.

IPC Classes  ?

• A61K 33/32 - ManganeseCompounds thereof
• A61P 39/00 - General protective or antinoxious agents
• A61K 9/107 - Emulsions
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
• A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
• A61K 47/28 - Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid

Abstract

The present invention relates to specific reverse micelle system of the invention which allows the administration and intracellular delivery of unmodified oligonucleotide, such as siRNA, targeting one or more genes of the SARS-CoV-2 virus. The reverse micelle system of the invention is thus particularly useful for the treatment of the viral pathology linked to the SARS-CoV-2 virus.

IPC Classes  ?

• A61K 9/107 - Emulsions
• A61K 47/28 - Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
• A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61P 31/14 - Antivirals for RNA viruses
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

The present disclosure relates to specific reverse micelle system that allows for the administration and intracellular delivery of unmodified oligonucleotide, such as siRNA, targeting one or more genes of the SARS-CoV-2 virus. The reverse micelle systems described herein are particularly useful for the treatment of COVID-19.

IPC Classes  ?

• A61K 9/107 - Emulsions
• A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
• A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
• A61K 47/28 - Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61P 31/14 - Antivirals for RNA viruses

Abstract

The present invention relates to specific reverse micelle system which allows the administration and intracellular delivery of unmodified oligonucleotide, such as siRNA, targeting genes linked to the interferon pathway, with a preference for the IFNAR1 gene. The reverse micelle system of the invention is thus particularly useful for the treatment of pathologies related to an overexpression of IFNAR1 gene. The reverse micelle system of the invention is also for use in combination with an oncolytic virus or composition thereof for the treatment of cancers. In particular embodiments, said cancers are resistant to oncolytic virus-based treatments and/or are characterized by an overexpression of IFNAR1 gene.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/107 - Emulsions
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61K 38/00 - Medicinal preparations containing peptides
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• A61K 35/768 - Oncolytic viruses not provided for in groups
• A61P 35/00 - Antineoplastic agents
• C07K 14/715 - ReceptorsCell surface antigensCell surface determinants for cytokinesReceptorsCell surface antigensCell surface determinants for lymphokinesReceptorsCell surface antigensCell surface determinants for interferons
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

The disclosure relates to the treatment and/or prevention of radiation damage by administering a reverse micelle system.

IPC Classes  ?

• A61K 33/32 - ManganeseCompounds thereof
• A61P 39/00 - General protective or antinoxious agents
• A61K 9/107 - Emulsions
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
• A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
• A61K 47/28 - Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid

Abstract

The present invention relates to specific reverse micelle system of the invention which allows the administration and intracellular delivery of unmodified oligonucleotide, such as siRNA, targeting one or more genes of the SARS-CoV-2 virus. The reverse micelle system of the invention is thus particularly useful for the treatment of the viral pathology linked to the SARS-CoV-2 virus.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• A61K 9/107 - Emulsions
• A61K 9/00 - Medicinal preparations characterised by special physical form

Goods & Services

Pharmaceutical products; veterinary products; dietetic foods for medical use; food supplements.

Goods & Services

Pharmaceutical products; veterinary products; dietetic foods for medical use; food supplements; chemical preparations for pharmaceutical use .

Goods & Services

Pharmaceutical products; veterinary products; dietetic foods for medical use; food supplements.

Abstract

The disclosure relates to the treatment and/or prevention of radiation damage by administering a reverse micelle system.

IPC Classes  ?

• A61K 9/107 - Emulsions
• A61K 49/00 - Preparations for testing in vivo

Abstract

A reverse micellar system for use in the treatment of a subject exposed to radiation and/or preventing radiation damage in a subject at risk for exposure to radiation. The reverse micellar system comprises at least a sterol, 50 to 90% by weight of acylglycerol, 1 to 20% by weight of lecithin, ethanol and water, and the weight ratio of lecithin to acylglycerol is from 0.05 to 0.4. The reverse micellar system is free of a chelator and of cyano-bridged metal nanoparticles.

IPC Classes  ?

• A61K 9/107 - Emulsions
• A61K 49/00 - Preparations for testing in vivo

Abstract

The present invention relates to a method for in situ preparation of cyano-bridged coordination polymers as metal nanoparticles within a biocompatible reverse micellar system by mixing at least two reverse micellar systems, each one containing at least one metal salt precursor. The invention also relates to the stabilization of theses nanoparticles by using a biocompatible reverse micellar system. This system takes part of the synthesis as a nanoreactor which comprises at least an acylglycerol, a sterol, lecithin, ethanol and water for the preparation of stable cyano-bridged metal nanoparticles without any use of additional stabilizer agent.

IPC Classes  ?

• A61K 33/32 - ManganeseCompounds thereof
• A61K 9/107 - Emulsions
• A61K 31/28 - Compounds containing heavy metals
• A61K 9/51 - Nanocapsules
• A61K 47/28 - Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
• A61K 31/26 - Cyanate or isocyanate estersThiocyanate or isothiocyanate esters
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 33/26 - IronCompounds thereof
• A61K 33/30 - ZincCompounds thereof
• A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids

Abstract

The present invention relates to reverse-micellar systems comprising at least an active agent, an acylglycerol, a sterol, lecithin, ethanol and water, for use in chelation and/or sequestering of a radionuclide and/or a metal in a patient. The invention also relates to the reverse-micellar systems and to pharmaceutical compositions comprising said reverse-micellar systems.

IPC Classes  ?

• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
• A61K 49/10 - Organic compounds
• A61K 49/18 - Nuclear magnetic resonance [NMR] contrast preparationsMagnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound

Abstract

The present invention relates to a method for in situ preparation of cyano-bridged coordination polymers as metal nanoparticles within a biocompatible reverse micellar system by mixing at least two reverse micellar systems, each one containing at least one metal salt precursor. The invention also relates to the stabilization of theses nanoparticles by using a biocompatible reverse micellar system. This system takes part of the synthesis as a nanoreactor which comprises at least an acylglycerol, a sterol, lecithin, ethanol and water for the preparation of stable cyano-bridged metal nanoparticles without any use of additional stabilizer agent.

IPC Classes  ?

• A61K 9/107 - Emulsions
• A61K 9/51 - Nanocapsules
• A61K 31/26 - Cyanate or isocyanate estersThiocyanate or isothiocyanate esters
• A61K 31/28 - Compounds containing heavy metals
• A61K 47/28 - Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid

Abstract

The present invention relates to reverse-micellar systems comprising at least an active agent, an acylglycerol, a sterol, lecithin, ethanol and water, for use in chelation and/or sequestering of a radionuclide and/or a metal in a patient. The invention also relates to the reverse-micellar systems and to pharmaceutical compositions comprising said reverse-micellar systems.

IPC Classes  ?

• A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
• A61P 39/04 - Chelating agents
• A61K 49/10 - Organic compounds
• A61K 49/18 - Nuclear magnetic resonance [NMR] contrast preparationsMagnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes

Abstract

The present invention deals with a new organogel formulation, comprising lecithin, water, ethanol and acylglycerols. Said organogel formulation can be used for therapeutical purposes, both per se and as matrix for a pharmaceutically or veterinary active agent. Said organogel formulation can also be used in the treatment of dermatological affections or as a matrix for cosmetic or personal care substances.

IPC Classes  ?

• A61K 8/04 - DispersionsEmulsions
• A61K 8/37 - Esters of carboxylic acids
• A61K 8/55 - Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing phosphorus
• A61K 8/63 - SteroidsDerivatives thereof
• A61Q 19/00 - Preparations for care of the skin
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/06 - OintmentsBases therefor
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
• A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
• A61K 47/28 - Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
• A61K 31/455 - Nicotinic acid, i.e. niacinDerivatives thereof, e.g. esters, amides
• A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
• A61K 33/30 - ZincCompounds thereof
• A61K 33/32 - ManganeseCompounds thereof

Abstract

The present invention relates to reverse micelle system based on sterols, acylglycerols, phospholipids or sphingolipids and nucleic acids. The reverse micelle system of the invention is able to cross mucosa and cellular membranes. It thus allows vectorization of nucleic acids to target sites. It is advantageously useful in the pharmaceutical and dietetic fields.

IPC Classes  ?

• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
• A61K 9/107 - Emulsions
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
• A61K 47/28 - Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle

Abstract

The present invention relates to reverse micelle system based on sterols, acylglycerols, phospholipids or sphingolipids and nucleic acids. The reverse micelle system of the invention is able to cross mucosa and cellular membranes. It thus allows vectorization of nucleic acids to target sites. It is advantageously useful in the pharmaceutical and dietetic fields.

IPC Classes  ?

• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy

Abstract

The present invention relates to reverse micelle system based on sterols, acylglycerols, phospholipids or sphingolipids and metal ions. Reverse micelle system of the invention is able to cross mucosa and cellular membranes. It thus allows vectorization of metal ions to target sites. It is advantageously useful in the pharmaceutical and dietetic fields.

IPC Classes  ?

• A61K 31/28 - Compounds containing heavy metals
• A61K 9/107 - Emulsions

Abstract

The present invention relates a method for treating neurodegenerative or related disorders by administering low doses of lithium. The invention also relates to pharmaceutical or dietary compositions comprising low content of lithium and uses thereof.

IPC Classes  ?

• A61K 31/28 - Compounds containing heavy metals
• A61K 33/24 - Heavy metalsCompounds thereof
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 25/16 - Anti-Parkinson drugs
• A61P 25/00 - Drugs for disorders of the nervous system

Abstract

The present invention relates to reverse micelle system based on sterols, acylglycerols, phospholipids or sphingo lipids and metal ions. Reverse micelle system of the invention is able to cross mucosa and cellular membranes. It thus allows vectorization of metal ions to target sites. It is advantageously useful in the pharmaceutical and dietetic fields.

IPC Classes  ?

• A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
• A61K 9/107 - Emulsions
• A23L 1/30 - containing additives (A23L 1/308 takes precedence);;
• A61K 31/28 - Compounds containing heavy metals

Abstract

The present invention relates to reverse micelle system based on sterols, acylglycerols, phospholipids or sphingolipids and nucleic acids. The reverse micelle system of the invention is able to cross mucosa and cellular membranes. It thus allows vectorization of nucleic acids to target sites. It is advantageously useful in the pharmaceutical and dietetic fields.

IPC Classes  ?

• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant